These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 26972555

  • 21. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry.
    Hsing AW, Stanczyk FZ, Bélanger A, Schroeder P, Chang L, Falk RT, Fears TR.
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1004-8. PubMed ID: 17507629
    [Abstract] [Full Text] [Related]

  • 22. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
    Bouchard C, Labrie F, Archer DF, Portman DJ, Koltun W, Elfassi É, Grainger DA, Ayotte N, Cooper TA, Martens M, Waldbaum AS, Labrie C, Côté I, Lavoie L, Martel C, Balser J, VVA Prasterone Group.
    Climacteric; 2015 May; 18(4):590-607. PubMed ID: 25511551
    [Abstract] [Full Text] [Related]

  • 23. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 May; 16(5):907-22. PubMed ID: 19436225
    [Abstract] [Full Text] [Related]

  • 24. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M, Monteleone P, Casarosa E, Quirici B, Puccetti S, Bernardi F, Genazzani AD, Rovati L, Luisi M, Genazzani AR.
    Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
    [Abstract] [Full Text] [Related]

  • 25. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause.
    Labrie F.
    J Steroid Biochem Mol Biol; 2015 Jan; 145():133-8. PubMed ID: 24923731
    [Abstract] [Full Text] [Related]

  • 26. Metabolism of DHEA in postmenopausal women following percutaneous administration.
    Labrie F, Bélanger A, Bélanger P, Bérubé R, Martel C, Cusan L, Gomez J, Candas B, Chaussade V, Castiel I, Deloche C, Leclaire J.
    J Steroid Biochem Mol Biol; 2007 Feb; 103(2):178-88. PubMed ID: 17084625
    [Abstract] [Full Text] [Related]

  • 27. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
    Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Côté I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur É, Members of the VVA Prasterone Group.
    Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
    [Abstract] [Full Text] [Related]

  • 28. Prasterone: A Review in Vulvovaginal Atrophy.
    Heo YA.
    Drugs Aging; 2019 Aug; 36(8):781-788. PubMed ID: 31290076
    [Abstract] [Full Text] [Related]

  • 29. Ovarian and adrenal contributions to peripheral steroid levels in postmenopausal women.
    Maroulis GB, Abraham GE.
    Obstet Gynecol; 1976 Aug; 48(2):150-4. PubMed ID: 133306
    [Abstract] [Full Text] [Related]

  • 30. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women.
    Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C.
    J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):178-94. PubMed ID: 18598765
    [Abstract] [Full Text] [Related]

  • 31. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
    Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Côté I, Lavoie L, Martel C, Balser J, VVA Prasterone Group.
    Menopause; 2015 Sep; 22(9):950-63. PubMed ID: 25734980
    [Abstract] [Full Text] [Related]

  • 32. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study.
    Bouchard C, Labrie F, Derogatis L, Girard G, Ayotte N, Gallagher J, Cusan L, Archer DF, Portman D, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E, VVA Prasterone Group.
    Horm Mol Biol Clin Investig; 2016 Mar; 25(3):181-90. PubMed ID: 26725467
    [Abstract] [Full Text] [Related]

  • 33. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging.
    Labrie F, Bélanger A, Cusan L, Gomez JL, Candas B.
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2396-402. PubMed ID: 9253307
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
    Montesino M, Labrie F, Archer DF, Zerhouni J, Côté I, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Moyneur E, Balser J.
    Gynecol Endocrinol; 2016 Aug; 32(3):240-5. PubMed ID: 26634942
    [Abstract] [Full Text] [Related]

  • 35. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
    Panjari M, Davis SR.
    Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
    [Abstract] [Full Text] [Related]

  • 36. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 Sep; 16(5):923-31. PubMed ID: 19424093
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics of oral dehydroepiandrosterone (DHEA) in the ovariectomised cynomolgus monkey.
    Leblanc M, Labrie C, Bélanger A, Candas B, Labrie F.
    J Steroid Biochem Mol Biol; 2002 Jun; 81(2):159-64. PubMed ID: 12137806
    [Abstract] [Full Text] [Related]

  • 38. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women.
    Labrie F, Bélanger A, Bélanger P, Bérubé R, Martel C, Cusan L, Gomez J, Candas B, Castiel I, Chaussade V, Deloche C, Leclaire J.
    J Steroid Biochem Mol Biol; 2006 Jun; 99(4-5):182-8. PubMed ID: 16621522
    [Abstract] [Full Text] [Related]

  • 39. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
    Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M.
    Menopause; 2017 Nov; 24(11):1246-1256. PubMed ID: 28640161
    [Abstract] [Full Text] [Related]

  • 40. Interaction of delta-5-androstene-3beta, 17beta-diol with estradiol and dihydrotestosterone receptors in human myometrial and mammary cancer tissue.
    Poortman J, Prenen JA, Schwarz F, Thijssen JH.
    J Clin Endocrinol Metab; 1975 Mar; 40(3):373-9. PubMed ID: 163841
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.